ArticleFrontiers in public health2025
Analysis on the hospitalization expenses structure and correlation degree of lung cancer: evidence from Shanxi Province, China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer is associated with a heavy economic burden in China. In this study, we analyzed the hospitalization expenses of patients with different types of lung cancer and investigated how the expense structure has changed from 2017 to 2021. Methods: A total of 17,721 patients were included. All patients with lung cancer discharged from a tertiary hospital in Shanxi, China. Hospitalization expenses were categorized as drug, treatment, medical material, diagnostic, nursing, operating, and other expenses. All expenses were inflated to the price of 2022. New grey correlation degree and structural change analyses were conducted. Results: Hospitalization expenses increased from 2017 to 2021 at a rate of 27.6%. Among all components, drug expenses were most significantly associated with hospitalization expenses. The expense structure of the hospitalization expenses also changed, with an overall structural variability of 41.74%. The top three contributors to changes were medical material, drug, and treatment expenses. The expense structure differed across lung cancer types. Conclusion: In summary, the medical expenses of lung cancer patients are increasing. Although the expense structure has changed, there is still plenty of scope for further optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.